Baseline Frequency of Inflammatory Cxcl9 Expressing Tumor-Associated Macrophages Predicts Response to Avelumab (anti-PDL-1) Treatment. Baseline Frequency of Inflammatory Cxcl9 Expressing Tumor-Associated Macrophages Predicts Response to Avelumab (anti-PDL-1) Treatment

scRNA-Sequencing of CD45+ TILs taken from a single tumor of a bilateral pair prior to avelumab treatment Overall design: CD45+ TILs were FACS purified from CT26 tumors resected 8 days post s.c. implantation. Tumor sampled was a single tumor belonging to a bilateral pair, following resection mice were treated with avelumab to allow correlation of pre-treatment tumor immune cell profiles with treatment response.